Bio­phar­ma man­u­fac­tur­ing ‘tur­bu­lence’ boosts in­quiries for In­dia-based providers, lo­cal CD­MO ex­ecs say

In­dia-based CD­MOs have de­tect­ed an uptick in bio­phar­ma client in­ter­est in their bi­o­log­ics and ear­ly-phase clin­i­cal of­fer­ings – and these man­u­fac­tur­ers are ac­cord­ing­ly ad­just­ing their growth strat­e­gy.

“There’s an in­crease in de­mand. There’s a lot of fac­tors that are go­ing on that are in­flu­enc­ing that,” En­zene Bio­sciences’ CEO Hi­man­shu Gadg­il told End­points News in an in­ter­view. En­zene es­pe­cial­ly has seen an in­crease in small to mid­size bio­phar­ma clients reach­ing out. “We will def­i­nite­ly be look­ing at be­ing more ag­gres­sive in terms of our ex­pan­sion plan,” he added.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER